Peter Thal Larsen
Peter is Asia Editor of Reuters Breakingviews, based in Hong Kong. He oversees coverage of financial services and regulation. Prior to joining Reuters, Peter spent 10 years at the Financial Times. From 2004 to 2009 he was the FT’s banking editor, leading the paper’s award-winning coverage of global banking during the credit crunch. Between 2000 and 2004 Peter reported for the FT from New York. He played a leading role in the paper’s coverage of the 9/11 attacks and their aftermath. A Dutch national, Peter has degrees from Bristol University and the London School of Economics. Follow Peter on Twitter @Peter_TL
- Tel: +852 2843 6300
- E-mail: email@example.com
The stock exchange is poised to launch a debate on shareholder voting rights after Alibaba cancelled its listing in the former colony. Dumping “one share, one vote” won’t necessarily attract many new IPOs. But it would undermine Hong Kong’s already shaky corporate governance.
Daiichi Sankyo is handing control of the troubled Indian drugmaker to local rival Sun Pharma in a $3.2 billion all-share deal. The investment has lost almost 40 percent of its value in six years. It’s a reminder of all that can go wrong when Japanese companies venture overseas.
Investors are getting excited about mainland shareholders being allowed to buy Hong Kong stocks. But as with any loosening of China’s capital controls, progress will be gradual. Though Chinese cash will increasingly leak onto global markets, any breakthrough remains some way off.
- OCBC’s Chinese ambition comes with hefty price tag
- China’s irrational bank run shows fragile trust
- Li & Fung revival depends on more than split
- Japan stock market selloff is a temporary setback
- Temasek buyout throws sovereign weight behind Olam
- China internet duo join forces against common foe
- Search for China’s “Bear Stearns moment” is flawed